1937 Alfa Romeo 8C 2900B Berlinetta Named the Most Prestigious Car in the World
8.2.2019 12:06:00 EET | Business Wire | Press release
Arguably one of the most desirable cars of all time, the remarkable 1937 Alfa Romeo 8C 2900B Berlinetta today was revealed at The Peninsula Paris hotel as the winner of the fourth annual The Peninsula Classics Best of the Best Award.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190208005130/en/
The 1937 ALFA ROMEO 8C 2900B BERLINETTA was named winner of The Peninsula Classics Best of the Best Award. (Photo: Jana Call me J)
While eight stunning ‘Best of Show’ winners from top concours around the world competed for the accolade, the Alfa Romeo was the stand-out choice among the judges as the best car in the world. Hailing from Los Angeles, California, the car was entered into the running for the award after being named ‘Best of Show’ at the 2018 Pebble Beach Concours d’Elegance.
“The winning Alfa Romeo is a perfect example of the type of car that inspired us to create this award,” said William E. (Chip) Connor, Chairman and CEO of William E. Connor & Associates Ltd, and co-founder of The Peninsula Classics Best of the Best Award. “To provide an opportunity for car lovers to pause a moment and celebrate flawless design and engineering of this calibre is truly an honour each year.”
The Alfa Romeo is owned by David and Ginny Sydorick of Los Angeles, California. Reflecting on the car’s recent recognition, David said: “As an avid auto-collector, having two cars in the running for this year’s award was truly remarkable. It goes without saying that Ginny and I are ecstatic at the result – a proud moment for us both.”
The winning car was unveiled using a ‘shutter-effect’, whereby individual slats turned in sync to reveal the Alfa Romeo standing proudly within a bespoke-designed, up-lit box. Following the big reveal, guests at the party, including ‘Beauty and the Beast,’ ‘The Alienist,’ and ‘Girl on a Train’ star Luke Evans, were further treated to a music set from notable DJ and On-Camera Personality, Hannah Bronfman, who was joined by husband, DJ and Entrepreneur, Brendan Fallis.
An automotive jewel engineered by Ingegner Vittorio Jano, the 8C 2900 was designed to compete in sports car races, specifically the Mille Miglia, which it won outright in 1935, 1936, 1937, 1938 and 1947. In racing trim, they dominated all the major competitions, and in road trim, they were the fastest grand touring cars.
Established in 1925 in Milan, Italian coachbuilder Carrozzeria Touring had first licensed Charles Weymann's system of fabric-covered lightweight frames and then developed its own ‘Superleggera’ construction. Patented in 1936, the Superleggera system consists of a structural framework of small-diameter steel tubes that conform to an automobile body's shape and are covered by thin alloy body panels that strengthen the framework. The winning vehicle, 412020, is the first of only five known Berlinettas built on the Lungo chassis and is the car that Touring refers to as the beginning of Superleggera.
About The Peninsula Classics Best of the Best Award
Through a shared desire to celebrate the best of what defines the automotive world, The Hon. Sir Michael Kadoorie, Chairman of The Hongkong and Shanghai Hotels, Limited, launched The Peninsula Classics Best of the Best Award in 2015 with co-founders William E. (Chip) Connor, Bruce Meyer and Christian Philippsen. Each founder shares a common passion and appreciation of fine motor cars, the preservation of their heritage and immaculate restoration projects. The award, sponsored by The Peninsula Hotels, brings together eight of the concours circuits’ elite ‘Best of Show’ winners from around the globe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190208005130/en/
Contact information
Media:
Sanaz Marbley/Devon Zahm
JMPR Public Relations
+1
(818) 992 4353
smarbley@jmpr.com
/ dzahm@jmpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom